D42E39B0-7962-4880-A182-4596DB01B202
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.4257555847569
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.527
- DNA_REPAIR+0.491
- MYC_TARGETS_V1+0.491
- OXIDATIVE_PHOSPHORYLATION+0.418
- NOTCH_SIGNALING+0.333
- CHOLESTEROL_HOMEOSTASIS+0.317
- WNT_BETA_CATENIN_SIGNALING+0.302
- INTERFERON_ALPHA_RESPONSE+0.252
- E2F_TARGETS+0.248
- PANCREAS_BETA_CELLS+0.194
Top 10 suppressed
- UV_RESPONSE_DN-0.376
- PROTEIN_SECRETION-0.290
- MITOTIC_SPINDLE-0.287
- ANDROGEN_RESPONSE-0.271
- KRAS_SIGNALING_DN-0.269
- TGF_BETA_SIGNALING-0.263
- TNFA_SIGNALING_VIA_NFKB-0.221
- ESTROGEN_RESPONSE_EARLY-0.154
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.149
- HYPOXIA-0.146
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DEACC29A-6DEF-4728-AFEB-15D7BDA850CA | — | — | 0.873 |
| 2 | F9FA52F2-BD53-4CE8-B227-5936AE06B76A | — | — | 0.857 |
| 3 | CA985B0C-E8F9-4682-ABAF-A0E482F7DF72 | — | — | 0.832 |
| 4 | FD76D38B-2A54-4F1A-B7C0-EF268F9D9A0E | — | — | 0.831 |
| 5 | 381221D6-D0E6-47B3-AB59-468AE2A5FC0A | — | — | 0.819 |
| 6 | 152AC0F4-B49F-49AE-BF76-45C70CA3FF7F | — | — | 0.806 |
| 7 | 9FCC850A-554E-4E56-95BA-F7F5CF0D5012 | — | — | 0.766 |
| 8 | 46C5EF69-5EAF-4FBA-BE47-28A8E7F3D9A2 | — | — | 0.761 |
| 9 | MNG602 | — | — | 0.754 |
| 10 | SRR11296846 | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.527 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.491 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.491 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.418 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.333 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.317 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.302 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.252 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.248 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.194 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.188 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.184 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.178 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.175 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.171 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.168 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.146 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.134 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.127 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.117 | Inavolisib | — uncovered |